1 / 2

Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)

A completely human monoclonal antibody called panitumumab targets the epidermal growth factor receptor (EGFR).<br><br>For More Information- https://www.delveinsight.com/asco-conference/article/panitumumab-mfolfox6-versus-bevacizumab?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage

yashb
Download Presentation

Takeda’s Flagship Product Panitumumab (PAN) mFOLFOX6 Versus bevacizumab (BEV)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1 Takeda’s Flagship Product Panitumumab (PAN) +mFOLFOX6 Versus bevacizumab mFOLFOX6 (BEV) + Panitumumab (PAN) + mFOLFOX6 Versus Bevacizumab Patients in the Takeda-sponsored Phase III research comparing PAN + mFOLFOX6 to BEV + mFOLFOX6 as the first-line treatment for metastatic colorectal cancer (mCRC) (mCRC) (LBA1 abstract) A completely human monoclonal antibody called panitumumab targets the epidermal growth factor receptor (EGFR). In 2019, the US FDA and the EMA approved panitumumab for the treatment of RAS wild-type metastatic colorectal cancer (mCRC) in combination with FOLFOX (5- fluorouracil, leucovorin, and oxaliplatin) or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) in the first-line setting, in combination with FOLFIRI in the second-line setting. At a median follow-up of 61 months in the PARADIGM trial, panitumumab significantly improved OS in both the population with left-sided malignancies and the entire study population. With panitumumab, the median PFS for the entire population was 12.9 months as opposed to 12 months with bevacizumab. In the group with left-sided tumors, the stratified hazard ratio (HR)

  2. 2 for mortality with panitumumab compared with bevacizumab was 0.82 (P =.031) and 0.84 (P =.030) in the complete analytic population. The group with left-sided tumors had median OS lengths of 37.9 months in the panitumumab arm and 34.3 months in the bevacizumab arm; however, the mPFS duration was not substantially different (13.7 vs. 13.2). The Response Rate, however, also supported panitumumab (80.2%). KOL insights According to Expert Opinion, "These data support the first-line use of panitumumab plus modified FOLFOX6 in patients with RAS wild-type and left-sided metastatic colorectal cancer." Conclusion Modified FOLFOX6 (mFOLFOX6) plus panitumumab significantly improved overall survival (OS) in patients with wild-type RAS metastatic colorectal cancer (mCRC) who had left-sided tumors when compared to mFOLFOX6 plus bevacizumab. No new safety signs were noticed, according to the study's researchers. The trial showed superiority with panitumumab over bevacizumab in combination with mFOLFOX6, they added. This was true for both left-sided tumors and the total mCRC populations. Companies- Mirati Therapeutics, Merck Sharp & Dohme, Pfizer, Ono Pharmaceutical, G1 Therapeutics, Daiichi Sankyo, AstraZeneca, and others. Also, read- ASCO Conference 2020 | ASCO 2020 Abstracts | ASCO 2021 Highlights ASCO Medical Conference | ASCO 2021 | ASCO 2021 Conference | when in ASCO 2021 | 2021 ASCO | ASCO US | ASCO 2022 Annual Meeting | ASCO Abstract 2022 | ASCO 2021 Abstracts

More Related